By: Anton Bespalov
Commentary: What if …
December 23, 2024Several years ago we discussed potential scenarios related to the outcome of Cassava’s Phase 3 program. To remind our readers, concerns…
Read MoreIntentional misconduct or too busy to oversee the lab?
December 23, 2024The recent scientific misconduct in the laboratories of Eliezer Masliah is not the first such case and will unfortunately most likely…
Read MoreUpcoming symposium: Assessment of benefit of animal research
December 23, 2024It is generally recognized that, to produce robust and reliable data, research must be protected against bias. There are various measures…
Read MoreImagine…
December 23, 2024… you go to a supermarket or a grocery store, buy everything you need, pay at the cashier’s but leave all…
Read MoreWebinar: Financing of biomedical innovation: Learning to separate the wheat from the chaff
December 23, 2024The misconduct case of Eliezer Masliah highlights once again existing challenges in allocating capital to projects with the most robust and…
Read MoreDon’t throw the baby out with the bathwater
December 22, 2023The pressure to replace animal research with non-animal methods is growing. Earlier this year, NIH has issued a “Request for Information…
Read More“Home inspections” for life sciences companies going public before clinical proof of concept
December 22, 2023For over a decade, there is a trend of less specialized investment firms and public equity investors betting on life sciences…
Read MoreSex as a biological variable in preclinical research: Unforeseen and abused degree of freedom
December 21, 2023In many fields of biomedical research, in vivo studies traditionally involved the use of male subjects. The situation recently started to…
Read More